Skip to main content
      In AxSpA, an 8-week personalized exercise program improved trunk strength (+14.1%), mobility (+14.9%), and cardiorespira

      Antoni Chan MD (Prof) synovialjoints

      6 days 8 hours ago
      In AxSpA, an 8-week personalized exercise program improved trunk strength (+14.1%), mobility (+14.9%), and cardiorespiratory fitness ( increased oxygen pulse, ventilatory efficiency, anaerobic threshold). BASDAI and chest expansion also improved. Supports tailored rehab based on https://t.co/jawosa2AJK
      #Ianalumab decreases disease activity in active #Sjögren's #disease

      2 phase3 DB #RCT added to #SoC in primary #SjD
      &g

      Janet Pope Janetbirdope

      6 days 8 hours ago
      #Ianalumab decreases disease activity in active #Sjögren's #disease 2 phase3 DB #RCT added to #SoC in primary #SjD >90% #Ro+ +#ESSDAI in monthly sc dosing vs placebo, Many 2ndary outcomes improved, safe LB#24 #ACR25 @ACRheum @RheumNow #ACRBest https://t.co/Z4ooUg7Nos
      In a PsA cohort (n=1291), higher BMI was independently linked to lower odds of achieving MDA—especially in TNFi-treate

      Antoni Chan MD (Prof) synovialjoints

      6 days 8 hours ago
      In a PsA cohort (n=1291), higher BMI was independently linked to lower odds of achieving MDA—especially in TNFi-treated patients. Impact was strongest in pain, skin, enthesitis, and PRO domains, not swollen joints. Each unit increase in BMI reduced MDA odds by 4–7%. Highlights https://t.co/TxO3HP51uk
      #2686 Using HR-pQCT, researchers tracked bone changes in RA & PsA. Seropositive RA showed worst bone density & m

      Mrinalini Dey DrMiniDey

      6 days 8 hours ago
      #2686 Using HR-pQCT, researchers tracked bone changes in RA & PsA. Seropositive RA showed worst bone density & microstructure, worsening with disease activity. TNFi, RTX & BARI improved MCP bone density, highlighting the impact of inflammation and treatment. @RheumNow #ACR25
      Will CAR-Treg Rx be helpful in active #refractory #rheumatoid #arthritis?

      Early data n=6 treated w low dose (3 per arm)

      Janet Pope Janetbirdope

      6 days 8 hours ago
      Will CAR-Treg Rx be helpful in active #refractory #rheumatoid #arthritis? Early data n=6 treated w low dose (3 per arm), ongoing and doses will escalate Improvemt in #clinical #disease #activity less inflammation on #synovial #biopsies 3 pts #LB23 #ACR25 @RheumNow @ACRheum https://t.co/PkhsvztVjx
      GLP-1 RA vs DPP4i & risk of rheumatic disease: propensity score matched cohort study using TriNetX
      🔹 Lower incide

      Akhil Sood MD, MS AkhilSoodMD

      6 days 8 hours ago
      GLP-1 RA vs DPP4i & risk of rheumatic disease: propensity score matched cohort study using TriNetX 🔹 Lower incidence of OA, RA & gout w/ GLP-1 RA 🔹 No significant differences for PsA, SSc, axSpA, or SLE @RheumNow #ACR25 https://t.co/BIVw3ajrFZ
      #2662
      Using Medicare data to emulate real-world RA-ILD trials, investigators compared RTX vs ABA, TOC, JAKi & TNFi
      N

      Mrinalini Dey DrMiniDey

      6 days 8 hours ago
      #2662 Using Medicare data to emulate real-world RA-ILD trials, investigators compared RTX vs ABA, TOC, JAKi & TNFi No sig differences in mortality, resp, hospitalisation or lung transplant across groups, suggesting other b/tsDMARDs may be as safe as RTX for RAILD @RheumNow #ACR25
      Abstract 2694: Neutrophil:Lymphocyte ratio (NLR)- a practical step towards clinical monitoring of interferon?

      Log₂NL

      Akhil Sood MD, MS AkhilSoodMD

      6 days 8 hours ago
      Abstract 2694: Neutrophil:Lymphocyte ratio (NLR)- a practical step towards clinical monitoring of interferon? Log₂NLR significantly correlated with all three IFN signatures across patients with SLE, systemic sclerosis, rheumatoid arthritis, and myositis @RheumNow #ACR25 https://t.co/ujaOQGvAUV
      #Deucravacitinib #Tyk2i in active #PsA to 52weeks
      #PBO was crossed over at 16weeks

      Ongoing improvement for high bar out

      Janet Pope Janetbirdope

      6 days 8 hours ago
      #Deucravacitinib #Tyk2i in active #PsA to 52weeks #PBO was crossed over at 16weeks Ongoing improvement for high bar outcomes ex % in #minimal #disease #activity #MDA #Xray #progression was reduced with real data (not imputed) #ACR2025 @RheumNow @ACRheum https://t.co/kAMym2x8HQ
      Abstract 2687: GLP-1 RA in PsA
      In combined Toronto + NYU cohort, GLP-1 RA significantly associated with reduced:
      - Weig

      Akhil Sood MD, MS AkhilSoodMD

      6 days 8 hours ago
      Abstract 2687: GLP-1 RA in PsA In combined Toronto + NYU cohort, GLP-1 RA significantly associated with reduced: - Weight, CRP, and pain scores - Each 1% reduction in body weight associated w/ TJC, DAPSA, EQ-5D (QoL), LDL, Systolic BP @RheumNow #ACR25 https://t.co/30lPDkALKs
      McDermott et al. Target trial emulation of different b/tsDMARDs in RA-ILD. RTX as SOC. No significant differences seen i

      Richard Conway RichardPAConway

      6 days 8 hours ago
      McDermott et al. Target trial emulation of different b/tsDMARDs in RA-ILD. RTX as SOC. No significant differences seen in hospitalisation or death. Trends to abatacept and JAKi looking better... @RheumNow #ACR25 Abstr#2662 #ACRBest https://t.co/ghHEKztvgz
      #PD1 Ab looks good and safe in active RA

      Rosnilimab, a Selective and Potent Depleter of Pathogenic T

      Many failed sever

      Janet Pope Janetbirdope

      6 days 8 hours ago
      #PD1 Ab looks good and safe in active RA Rosnilimab, a Selective and Potent Depleter of Pathogenic T Many failed several Rx already No safety signals compared to another PD1i Proof of benefit in biospecimens too! abst#LB19 #ACR25 @RheumNow @ACRheum #ACRBest https://t.co/TmEOCfuHZU
      Biologic choice in PsA: consider factoring in obesity ⚖️

      Abstract 2691: In a longitudinal cohort study, obesity ass

      Akhil Sood MD, MS AkhilSoodMD

      6 days 8 hours ago
      Biologic choice in PsA: consider factoring in obesity ⚖️ Abstract 2691: In a longitudinal cohort study, obesity associated with ↓ odds of achieving minimal disease activity (MDA) among pts on TNFi, but not with other DMARDs @RheumNow #ACR25 https://t.co/p4KaH6HKYj
      #2661 In >5000 veterans with RA-ILD, 8 distinct FVC trajectories were identified. >1/2showed a progressive decline

      Mrinalini Dey DrMiniDey

      6 days 8 hours ago
      #2661 In >5000 veterans with RA-ILD, 8 distinct FVC trajectories were identified. >1/2showed a progressive decline (≥0.7%/yr). These progressive patterns predicted higher mortality & respiratory hospitalisations, underscoring major disease heterogeneity. @RheumNow #ACR25
      TAC+MMF + GC vs TAC +GC in lupus nephritis (target trial emulation):
      🔹Higher total renal response w/ TAC + MMF + GC a

      Akhil Sood MD, MS AkhilSoodMD

      6 days 8 hours ago
      TAC+MMF + GC vs TAC +GC in lupus nephritis (target trial emulation): 🔹Higher total renal response w/ TAC + MMF + GC at 12 mo (59.7% vs 33.3%) consistent in ITT & per-protocol 🔹similar adverse events reported (14.6% vs 16.4%) @RheumNow #ACR25 https://t.co/Yuql3O9C8X
      ×